|
|
|
|
|
|
|
|
|
|
|
|
|
15.12.25 - 14:42
|
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders′ Meeting (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share capital) were at the Meeting, either in person or represented by proxy....
|
|
|
09.12.25 - 14:03
|
ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting (GlobeNewswire EN)
|
|
|
MADRID, SPAIN and CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today reported updated data from clinical studies investigating iadademstat, the Company's selective LSD1 inhibitor for onco-hematology indications. The results, recently presented at the 67th American Society of Hematology (ASH) Annual Meeting, highlight encouraging efficacy and safety findings from two ongoing studies evaluating iadademstat in combination with standard-of-care regimens in patients with acute myeloid leukemia (AML)....
|
|
|
14.11.25 - 17:42
|
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy (Benzinga)
|
|
|
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026.
Latest Ratings for BMY
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight
View More Analyst Ratings for BMY
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
Almirall′s 2025 9M Results (Business Wire)
|
|
|
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress
Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology.
EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength.
Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch.
Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a to...
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 19:18
|
Grifols 9-Month Profit Rises 245% (AFX)
|
|
|
MADRID (dpa-AFX) - Healthcare company Grifols (GRFS) on Tuesday reported a net profit of 304 million euros for the first nine months, up 245% compared to 88 million euros for the same period of 20......
|
|
|
03.11.25 - 14:03
|
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults with sickle cell disease (SCD). The study, to be conducted across several sites in Spain, aims to enroll approximately 40 adult patients. It is designed to evaluate the safety and tolerability of iadademstat in SCD and to establish the recommended Phase 2 dose (RP2D) as well as to evaluate iadademstat's effect on inducing fetal hemoglobin (HbF) expression. Increases in HbF have already been recognized by the FDA as a clinically meaningful endpoint for the treatment of SCD....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
